Compare PRFX & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRFX | VTAK |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.9M |
| IPO Year | 2020 | 2018 |
| Metric | PRFX | VTAK |
|---|---|---|
| Price | $1.35 | $0.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.0M | ★ 3.4M |
| Earning Date | 03-26-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $442,000.00 |
| Revenue This Year | N/A | $1,170.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3057.14 |
| 52 Week Low | $0.58 | $0.15 |
| 52 Week High | $5.39 | $4.31 |
| Indicator | PRFX | VTAK |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 38.84 |
| Support Level | $1.27 | N/A |
| Resistance Level | $1.45 | $0.93 |
| Average True Range (ATR) | 0.41 | 0.18 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 0.58 | 0.01 |
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.